| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[25] Low molecular weight heparin (first line option - prophylaxis): National Department of Health: Affordable Medicines, EDP-Adult Hospital Level. Medicine Review LMWH vs. UFH for the prophylaxis and treatment of venous thromboembolism and acute coronary syndromes, April 2018. http://www.health.gov.za/
Low molecular weight heparin (first line option - prophylaxis): Junqueira DR, Zorzela LM, Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in
postoperative patients. Cochrane Database Syst Rev. 2017 Apr 21;4:CD007557. https://www.ncbi.nlm.nih.gov/pubmed/28431186
Low molecular weight heparin (first line option - prophylaxis): Wein L, Wein S, Haas SJ, Shaw J, Krum H. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of
randomized controlled trials. Arch Intern Med. 2007 Jul 23;167(14):1476-86. https://www.ncbi.nlm.nih.gov/pubmed/17646601
Low molecular weight heparin (first line option - prophylaxis): National Department of Health: Affordable Medicines, EDP- Adult Hospital Level. Cost-effectiveness and budget impact analyses: Fondaparinux for prophylaxis of venous thromboembolism in medical and surgical patients in hospitalised patients in the South African public health system, April 2018. http://www.health.gov.za/
Low molecular weight heparin (first line option - treatment): National Department of Health: Affordable Medicines, EDP- Adult Hospital Level. Cost-effectiveness and budget impact analyses: Fondaparinux for the treatment of venous thromboembolism in hospitalised patients in the South African public health system, April 2018. http://www.health.gov.za/